Here, we addressed these questions in the context of T. cruzi infection over time and following treatment with either the standard-of-care antiparasitic BNZ12, or an experimental combination of BNZ and Tc24-C4 therapeutic vaccine, with a focus on infection-induced small molecule alterations. Here, C4A is linked to infection.